Literature DB >> 26928855

Clinicopathological Characteristics and Prognostic Factors of Patients with Siewert Type II Esophagogastric Junction Carcinoma: A Retrospective Multicenter Study.

Tatsuo Matsuda1,2, Yukinori Kurokawa3, Takaki Yoshikawa4, Kentaro Kishi5, Kazunari Misawa6, Masaki Ohi7, Shinji Mine2, Naoki Hiki8, Hiroya Takeuchi9.   

Abstract

BACKGROUND: The incidence of esophagogastric junction (EGJ) carcinoma is increasing, but its optimal surgical management remains controversial.
METHODS: We retrospectively reviewed the database of 400 patients with Siewert type II EGJ carcinoma who were treated surgically at 7 institutions between March 1986 and October 2010. We examined the clinicopathological characteristics, prognostic factors, and risk factors associated with each recurrence pattern.
RESULTS: The 5-year overall survival rate of all patients with Siewert type II EGJ carcinoma was 58.4 %. Multivariate analysis showed that T and N stages were independent prognostic factors. We also found that the incidence of lower mediastinal lymph node metastasis (17.7 %) and para-aortic lymph node metastasis (16.1 %) was relatively high. In addition, the para-aortic lymph nodes (N = 39, 9.8 %) were the most frequent node recurrence site, followed by the mediastinal lymph nodes (N = 23, 5.8 %). Lung recurrence was more common than was peritoneal recurrence. Considering each type of recurrence, multivariate analysis showed that the differentiated type was associated with a higher risk of lung recurrence than was the undifferentiated type, and N stage (pN2-3) and positive venous invasion were independent risk factors for liver recurrence.
CONCLUSIONS: This study is one of the largest retrospective studies to evaluate patients with Siewert type II EGJ carcinoma. Para-aortic and mediastinal lymph node metastasis and recurrence rates were relatively high. During the postoperative follow-up of patients with differentiated Siewert type II EGJ carcinoma, patients should be monitored for lung recurrence more closely than that for peritoneal recurrence.

Entities:  

Mesh:

Year:  2016        PMID: 26928855     DOI: 10.1007/s00268-016-3451-z

Source DB:  PubMed          Journal:  World J Surg        ISSN: 0364-2313            Impact factor:   3.352


  16 in total

1.  Postoperative outcome and sites of recurrence in patients following curative resection of gastric cancer.

Authors:  Y Maehara; S Hasuda; T Koga; E Tokunaga; Y Kakeji; K Sugimachi
Journal:  Br J Surg       Date:  2000-03       Impact factor: 6.939

2.  Esophageal and gastric carcinoma in Norway 1958-1992: incidence time trend variability according to morphological subtypes and organ subsites.

Authors:  S Hansen; J N Wiig; K E Giercksky; S Tretli
Journal:  Int J Cancer       Date:  1997-05-02       Impact factor: 7.396

3.  Left thoracoabdominal approach versus abdominal-transhiatal approach for gastric cancer of the cardia or subcardia: a randomised controlled trial.

Authors:  Mitsuru Sasako; Takeshi Sano; Seiichiro Yamamoto; Motonori Sairenji; Kuniyoshi Arai; Taira Kinoshita; Atsushi Nashimoto; Masahiro Hiratsuka
Journal:  Lancet Oncol       Date:  2006-08       Impact factor: 41.316

4.  Classification of adenocarcinoma of the oesophagogastric junction.

Authors:  J R Siewert; H J Stein
Journal:  Br J Surg       Date:  1998-11       Impact factor: 6.939

5.  The recurrence pattern of esophageal carcinoma after transhiatal resection.

Authors:  J B Hulscher; J W van Sandick; J G Tijssen; H Obertop; J J van Lanschot
Journal:  J Am Coll Surg       Date:  2000-08       Impact factor: 6.113

6.  Optimal extent of lymph node dissection for Siewert type II esophagogastric junction carcinoma.

Authors:  Hiroharu Yamashita; Hitoshi Katai; Shinji Morita; Makoto Saka; Hirokazu Taniguchi; Takeo Fukagawa
Journal:  Ann Surg       Date:  2011-08       Impact factor: 12.969

7.  D2 lymphadenectomy alone or with para-aortic nodal dissection for gastric cancer.

Authors:  Mitsuru Sasako; Takeshi Sano; Seiichiro Yamamoto; Yukinori Kurokawa; Atsushi Nashimoto; Akira Kurita; Masahiro Hiratsuka; Toshimasa Tsujinaka; Taira Kinoshita; Kuniyoshi Arai; Yoshitaka Yamamura; Kunio Okajima
Journal:  N Engl J Med       Date:  2008-07-31       Impact factor: 91.245

8.  Changing patterns in the incidence of esophageal and gastric carcinoma in the United States.

Authors:  S S Devesa; W J Blot; J F Fraumeni
Journal:  Cancer       Date:  1998-11-15       Impact factor: 6.860

9.  Rising incidence of adenocarcinoma of the esophagus and gastric cardia.

Authors:  W J Blot; S S Devesa; R W Kneller; J F Fraumeni
Journal:  JAMA       Date:  1991-03-13       Impact factor: 56.272

10.  Clinicopathological characteristics and optimal management for esophagogastric junctional cancer; a single center retrospective cohort study.

Authors:  Hiroaki Ito; Haruhiro Inoue; Noriko Odaka; Hitoshi Satodate; Michitaka Suzuki; Shumpei Mukai; Yusuke Takehara; Hiroyuki Kida; Shin-Ei Kudo
Journal:  J Exp Clin Cancer Res       Date:  2013-01-07
View more
  14 in total

1.  Clinicopathological Characteristics and Prognostic Factors of Patients with Siewert Type II Esophagogastric Junction Carcinoma: A Retrospective Multicenter Study: Reply.

Authors:  Tatsuo Matsuda; Hiroya Takeuchi
Journal:  World J Surg       Date:  2017-05       Impact factor: 3.352

2.  Changing the Rules of Resectability of T4b Esophageal Cancer Invading Aorta.

Authors:  Dimitrios Schizas; Demetrios Moris; Theodoros Liakakos
Journal:  World J Surg       Date:  2017-05       Impact factor: 3.352

Review 3.  Surgical approaches to adenocarcinoma of the gastroesophageal junction: the Siewert II conundrum.

Authors:  Andrew M Brown; Danica N Giugliano; Adam C Berger; Michael J Pucci; Francesco Palazzo
Journal:  Langenbecks Arch Surg       Date:  2017-08-12       Impact factor: 3.445

4.  Results of a nation-wide retrospective study of lymphadenectomy for esophagogastric junction carcinoma.

Authors:  Hiroharu Yamashita; Yasuyuki Seto; Takeshi Sano; Hiroyasu Makuuchi; Nobutoshi Ando; Mitsuru Sasako
Journal:  Gastric Cancer       Date:  2016-10-28       Impact factor: 7.370

5.  Comparison of long-term outcomes of endoscopic submucosal dissection and surgery for esophagogastric junction adenocarcinoma.

Authors:  Eun Jeong Gong; Do Hoon Kim; Ji Yong Ahn; Kee Wook Jung; Jeong Hoon Lee; Kee Don Choi; Ho June Song; Gin Hyug Lee; Hwoon-Yong Jung; Hee Sung Kim; In-Seob Lee; Beom Su Kim; Moon-Won Yoo; Sung Tae Oh; Jeong Hwan Yook; Byung Sik Kim
Journal:  Gastric Cancer       Date:  2016-12-19       Impact factor: 7.370

6.  Long-term outcomes of superficial neoplasia at the esophagogastric junction treated via endoscopic submucosal dissection and endoscopic submucosal tunnel dissection: a cohort study of a single center from China.

Authors:  Shengzhen Liu; Ningli Chai; Zhongsheng Lu; Huikai Li; Ying Xiong; Yaqi Zhai; Enqiang Linghu
Journal:  Surg Endosc       Date:  2019-04-16       Impact factor: 4.584

7.  Prognostic nomogram for Siewert type II adenocarcinoma of the esophagogastric junction patients with and without neoadjuvant radiotherapy: a retrospective cohort study.

Authors:  Zhenjiang Guo; Ning Wang; Fangzhen Liu; Qun Zhao
Journal:  Am J Transl Res       Date:  2022-01-15       Impact factor: 4.060

8.  Nomograms for Predicting Disease-Free Survival in Patients With Siewert Type II/III Adenocarcinoma of the Esophagogastric Junction Receiving Neoadjuvant Therapy and Radical Surgery.

Authors:  Zhenjiang Guo; Honghai Guo; Yuan Tian; Ze Zhang; Qun Zhao
Journal:  Front Oncol       Date:  2022-06-08       Impact factor: 5.738

9.  Distribution of lymph node metastases in locally advanced adenocarcinomas of the esophagogastric junction (cT2-4): comparison between Siewert type I and selected Siewert type II tumors.

Authors:  Akio Sakaki; Jun Kanamori; Koshiro Ishiyama; Daisuke Kurita; Junya Oguma; Hiroyuki Daiko
Journal:  Langenbecks Arch Surg       Date:  2020-06-08       Impact factor: 3.445

10.  ASO Author Reflections: Diagnostic Significance of Extramural Venous Invasion in Patients with Locally Advanced Esophageal Cancer.

Authors:  Zohra Faiz; Gursah Kats-Ugurlu; John T M Plukker
Journal:  Ann Surg Oncol       Date:  2018-10-31       Impact factor: 5.344

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.